Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1990 Sep;58(9):3020–3028. doi: 10.1128/iai.58.9.3020-3028.1990

Mutants of staphylococcal toxic shock syndrome toxin 1: mitogenicity and recognition by a neutralizing monoclonal antibody.

L Blanco 1, E M Choi 1, K Connolly 1, M R Thompson 1, P F Bonventre 1
PMCID: PMC313605  PMID: 1696937

Abstract

Toxic shock syndrome toxin 1 (TSST-1), a 22-kilodalton protein made by strains of Staphylococcus aureus harboring the chromosomal toxin gene, may elicit toxic shock syndrome in humans. In vitro, TSST-1 induces T cells to proliferate and macrophages to secrete interleukin-1. To conduct a structure-function analysis, point mutations on the TSST-1 gene were generated by site-directed mutagenesis to identify amino acids critical for activity of the toxin. Specific tyrosine and histidine residues were replaced by alanines. Wild-type and mutant TSST-1 gene constructs were expressed in Escherichia coli, and the products were tested for their mitogenic potential and reactivity with a TSST-1 neutralizing monoclonal antibody (MAb 8-5-7). Four of the mutants were similar to the wild type; i.e., the mutant toxins stimulated murine T cells and reacted with MAb 8-5-7 equally as well as the wild type. Two mutants exhibited a decrease in mitogenic activity, but one of these retained the capacity to bind with MAb 8-5-7 while the other was no longer recognized by the same antibody. One double mutant demonstrated minimal mitogenic activity and did not react in enzyme-linked immunosorbent and immunoblot assays with MAb 8-5-7. The data show that specific residues near the carboxy terminus of TSST-1 are essential for mitogenic activity and in forming the epitope recognized by neutralizing MAb 8-5-7.

Full text

PDF
3020

Images in this article

3023Image
on p.3023

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bergdoll M. S., Crass B. A., Reiser R. F., Robbins R. N., Davis J. P. A new staphylococcal enterotoxin, enterotoxin F, associated with toxic-shock-syndrome Staphylococcus aureus isolates. Lancet. 1981 May 9;1(8228):1017–1021. doi: 10.1016/s0140-6736(81)92186-3. [DOI] [PubMed] [Google Scholar]
  2. Best G. K., Scott D. F., Kling J. M., Thompson M. R., Adinolfi L. E., Bonventre P. F. Protection of rabbits in an infection model of toxic shock syndrome (TSS) by a TSS toxin-1-specific monoclonal antibody. Infect Immun. 1988 Apr;56(4):998–999. doi: 10.1128/iai.56.4.998-999.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Blomster-Hautamaa D. A., Kreiswirth B. N., Kornblum J. S., Novick R. P., Schlievert P. M. The nucleotide and partial amino acid sequence of toxic shock syndrome toxin-1. J Biol Chem. 1986 Nov 25;261(33):15783–15786. [PubMed] [Google Scholar]
  4. Blomster-Hautamaa D. A., Novick R. P., Schlievert P. M. Localization of biologic functions of toxic shock syndrome toxin-1 by use of monoclonal antibodies and cyanogen bromide-generated toxin fragments. J Immunol. 1986 Dec 1;137(11):3572–3576. [PubMed] [Google Scholar]
  5. Bonventre P. F., Linnemann C., Weckbach L. S., Staneck J. L., Buncher C. R., Vigdorth E., Ritz H., Archer D., Smith B. Antibody responses to toxic-shock-syndrome (TSS) toxin by patients with TSS and by healthy staphylococcal carriers. J Infect Dis. 1984 Nov;150(5):662–666. doi: 10.1093/infdis/150.5.662. [DOI] [PubMed] [Google Scholar]
  6. Bonventre P. F., Thompson M. R., Adinolfi L. E., Gillis Z. A., Parsonnet J. Neutralization of toxic shock syndrome toxin-1 by monoclonal antibodies in vitro and in vivo. Infect Immun. 1988 Jan;56(1):135–141. doi: 10.1128/iai.56.1.135-141.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Bonventre P. F., Weckbach L., Staneck J., Schlievert P. M., Thompson M. Production of staphylococcal enterotoxin F and pyrogenic exotoxin C by Staphylococcus aureus isolates from toxic shock syndrome-associated sources. Infect Immun. 1983 Jun;40(3):1023–1029. doi: 10.1128/iai.40.3.1023-1029.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Calvano S. E., Quimby F. W., Antonacci A. C., Reiser R. F., Bergdoll M. S., Dineen P. Analysis of the mitogenic effects of toxic shock toxin on human peripheral blood mononuclear cells in vitro. Clin Immunol Immunopathol. 1984 Oct;33(1):99–110. doi: 10.1016/0090-1229(84)90296-4. [DOI] [PubMed] [Google Scholar]
  9. Chatila T., Wood N., Parsonnet J., Geha R. S. Toxic shock syndrome toxin-1 induces inositol phospholipid turnover, protein kinase C translocation, and calcium mobilization in human T cells. J Immunol. 1988 Feb 15;140(4):1250–1255. [PubMed] [Google Scholar]
  10. Choi Y. W., Kotzin B., Herron L., Callahan J., Marrack P., Kappler J. Interaction of Staphylococcus aureus toxin "superantigens" with human T cells. Proc Natl Acad Sci U S A. 1989 Nov;86(22):8941–8945. doi: 10.1073/pnas.86.22.8941. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Edwin C., Kass E. H. Identification of functional antigenic segments of toxic shock syndrome toxin 1 by differential immunoreactivity and by differential mitogenic responses of human peripheral blood mononuclear cells, using active toxin fragments. Infect Immun. 1989 Jul;57(7):2230–2236. doi: 10.1128/iai.57.7.2230-2236.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Fraser J. D. High-affinity binding of staphylococcal enterotoxins A and B to HLA-DR. Nature. 1989 May 18;339(6221):221–223. doi: 10.1038/339221a0. [DOI] [PubMed] [Google Scholar]
  13. Garbe P. L., Arko R. J., Reingold A. L., Graves L. M., Hayes P. S., Hightower A. W., Chandler F. W., Broome C. V. Staphylococcus aureus isolates from patients with nonmenstrual toxic shock syndrome. Evidence for additional toxins. JAMA. 1985 May 3;253(17):2538–2542. [PubMed] [Google Scholar]
  14. Jupin C., Anderson S., Damais C., Alouf J. E., Parant M. Toxic shock syndrome toxin 1 as an inducer of human tumor necrosis factors and gamma interferon. J Exp Med. 1988 Mar 1;167(3):752–761. doi: 10.1084/jem.167.3.752. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Kaplan E. H. Needles that kill: modeling human immunodeficiency virus transmission via shared drug injection equipment in shooting galleries. Rev Infect Dis. 1989 Mar-Apr;11(2):289–298. doi: 10.1093/clinids/11.2.289. [DOI] [PubMed] [Google Scholar]
  16. Kokan-Moore N. P., Bergdoll M. S. Effect of chemical modification of histidine and tyrosine residues in toxic shock syndrome toxin 1 on the serologic and mitogenic activities of the toxin. Infect Immun. 1989 Jul;57(7):1901–1905. doi: 10.1128/iai.57.7.1901-1905.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Kondo T., FitzGerald D., Chaudhary V. K., Adhya S., Pastan I. Activity of immunotoxins constructed with modified Pseudomonas exotoxin A lacking the cell recognition domain. J Biol Chem. 1988 Jul 5;263(19):9470–9475. [PubMed] [Google Scholar]
  18. Kreiswirth B. N., Handley J. P., Schlievert P. M., Novick R. P. Cloning and expression of streptococcal pyrogenic exotoxin A and staphylococcal toxic shock syndrome toxin-1 in Bacillus subtilis. Mol Gen Genet. 1987 Jun;208(1-2):84–87. doi: 10.1007/BF00330426. [DOI] [PubMed] [Google Scholar]
  19. Kunkel T. A. Rapid and efficient site-specific mutagenesis without phenotypic selection. Proc Natl Acad Sci U S A. 1985 Jan;82(2):488–492. doi: 10.1073/pnas.82.2.488. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Kyhse-Andersen J. Electroblotting of multiple gels: a simple apparatus without buffer tank for rapid transfer of proteins from polyacrylamide to nitrocellulose. J Biochem Biophys Methods. 1984 Dec;10(3-4):203–209. doi: 10.1016/0165-022x(84)90040-x. [DOI] [PubMed] [Google Scholar]
  21. Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970 Aug 15;227(5259):680–685. doi: 10.1038/227680a0. [DOI] [PubMed] [Google Scholar]
  22. Murphy B. G., Kreiswirth B. N., Novick R. P., Schlievert P. M. Localization of a biologically important epitope on toxic-shock-syndrome toxin-1. J Infect Dis. 1988 Sep;158(3):549–555. doi: 10.1093/infdis/158.3.549. [DOI] [PubMed] [Google Scholar]
  23. Nickol A. D., Bonventre P. F. Visceral leishmaniasis in congenic mice of susceptible and resistant phenotypes: immunosuppression by adherent spleen cells. Infect Immun. 1985 Oct;50(1):160–168. doi: 10.1128/iai.50.1.160-168.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Norton S. D., Schlievert P. M., Novick R. P., Jenkins M. K. Molecular requirements for T cell activation by the staphylococcal toxic shock syndrome toxin-1. J Immunol. 1990 Mar 15;144(6):2089–2095. [PubMed] [Google Scholar]
  25. Parsonnet J., Gillis Z. A., Richter A. G., Pier G. B. A rabbit model of toxic shock syndrome that uses a constant, subcutaneous infusion of toxic shock syndrome toxin 1. Infect Immun. 1987 May;55(5):1070–1076. doi: 10.1128/iai.55.5.1070-1076.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Parsonnet J., Hickman R. K., Eardley D. D., Pier G. B. Induction of human interleukin-1 by toxic-shock-syndrome toxin-1. J Infect Dis. 1985 Mar;151(3):514–522. doi: 10.1093/infdis/151.3.514. [DOI] [PubMed] [Google Scholar]
  27. Poindexter N. J., Schlievert P. M. Toxic-shock-syndrome toxin 1-induced proliferation of lymphocytes: comparison of the mitogenic response of human, murine, and rabbit lymphocytes. J Infect Dis. 1985 Jan;151(1):65–72. doi: 10.1093/infdis/151.1.65. [DOI] [PubMed] [Google Scholar]
  28. Sanger F., Nicklen S., Coulson A. R. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A. 1977 Dec;74(12):5463–5467. doi: 10.1073/pnas.74.12.5463. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Schlievert P. M., Shands K. N., Dan B. B., Schmid G. P., Nishimura R. D. Identification and characterization of an exotoxin from Staphylococcus aureus associated with toxic-shock syndrome. J Infect Dis. 1981 Apr;143(4):509–516. doi: 10.1093/infdis/143.4.509. [DOI] [PubMed] [Google Scholar]
  30. Schlievert P. M. Staphylococcal enterotoxin B and toxic-shock syndrome toxin-1 are significantly associated with non-menstrual TSS. Lancet. 1986 May 17;1(8490):1149–1150. doi: 10.1016/s0140-6736(86)91859-3. [DOI] [PubMed] [Google Scholar]
  31. Strickler M. P., Neill R. J., Stone M. J., Hunt R. E., Brinkley W., Gemski P. Rapid purification of staphylococcal enterotoxin B by high-pressure liquid chromatography. J Clin Microbiol. 1989 May;27(5):1031–1035. doi: 10.1128/jcm.27.5.1031-1035.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Vergeront J. M., Stolz S. J., Crass B. A., Nelson D. B., Davis J. P., Bergdoll M. S. Prevalence of serum antibody to staphylococcal enterotoxin F among Wisconsin residents: implications for toxic-shock syndrome. J Infect Dis. 1983 Oct;148(4):692–698. doi: 10.1093/infdis/148.4.692. [DOI] [PubMed] [Google Scholar]
  33. White J., Herman A., Pullen A. M., Kubo R., Kappler J. W., Marrack P. The V beta-specific superantigen staphylococcal enterotoxin B: stimulation of mature T cells and clonal deletion in neonatal mice. Cell. 1989 Jan 13;56(1):27–35. doi: 10.1016/0092-8674(89)90980-x. [DOI] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES